

# Eirini P Papapetrou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/958088/publications.pdf>

Version: 2024-02-01

62  
papers

7,732  
citations

201385

27  
h-index

149479

56  
g-index

86  
all docs

86  
docs citations

86  
times ranked

12764  
citing authors

#	ARTICLE	IF	CITATIONS
1	MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. <i>Blood</i> , 2022, 139, 205-216.	0.6	19
2	Integrative RNA-omics Discovers <i>GNAS</i> Alternative Splicing as a Phenotypic Driver of Splicing Factor-Mutant Neoplasms. <i>Cancer Discovery</i> , 2022, 12, 836-855.	7.7	19
3	Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of <i>SF3B1</i> -mutant HSPCs. <i>Blood Advances</i> , 2022, 6, 2992-3005.	2.5	7
4	MDS/AML with del5q: An acquired <i>α</i> -laminopathy?. <i>Cell Stem Cell</i> , 2022, 29, 498-499.	5.2	0
5	Studying leukemia stem cell properties and vulnerabilities with human iPSCs. <i>Stem Cell Research</i> , 2021, 50, 102117.	0.3	3
6	Restoring <i>RUNX1</i> deficiency in <i>RUNX1</i> familial platelet disorder by inhibiting its degradation. <i>Blood Advances</i> , 2021, 5, 687-699.	2.5	12
7	The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. <i>Nature</i> , 2021, 592, 296-301.	13.7	236
8	Reprogramming and cancer. <i>Stem Cell Research</i> , 2021, 52, 102249.	0.3	2
9	Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. <i>Cell Stem Cell</i> , 2021, 28, 1074-1089.e7.	5.2	37
10	Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells. <i>Current Opinion in Hematology</i> , 2021, 28, 50-56.	1.2	6
11	Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells. <i>Methods in Molecular Biology</i> , 2021, 2185, 411-422.	0.4	1
12	Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. <i>Circulation</i> , 2021, 144, 1940-1954.	1.6	33
13	Isogenic MDS-RS Patient-Derived iPSCs Define the Mis-Spliced Transcript Repertoire and Chromatin Landscape of <i>SF3B1</i> -Mutant Hematopoietic Stem/Progenitor Cells. <i>Blood</i> , 2021, 138, 147-147.	0.6	0
14	Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein. <i>Scientific Reports</i> , 2021, 11, 24432.	1.6	51
15	Acute Myeloid Leukemia iPSCs Reveal a Role for <i>RUNX1</i> in the Maintenance of Human Leukemia Stem Cells. <i>Cell Reports</i> , 2020, 31, 107688.	2.9	31
16	Engineering of targeted megabase-scale deletions in human induced pluripotent stem cells. <i>Experimental Hematology</i> , 2020, 87, 25-32.	0.2	5
17	<i>SF3B1</i> mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. <i>Leukemia</i> , 2020, 34, 2525-2530.	3.3	61
18	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. <i>Cancer Cell</i> , 2019, 36, 194-209.e9.	7.7	184

#	ARTICLE	IF	CITATIONS
19	Modeling Leukemia with Human Induced Pluripotent Stem Cells. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034868.	2.9	7
20	Modeling blood diseases with human induced pluripotent stem cells. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	23
21	Modeling myeloid malignancies with patient-derived iPSCs. Experimental Hematology, 2019, 71, 77-84.	0.2	18
22	Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells. JCI Insight, 2019, 4, .	2.3	10
23	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports, 2018, 10, 1610-1624.	2.3	43
24	TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells. Nature Genetics, 2018, 50, 83-95.	9.4	156
25	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	5.2	114
26	Gene and Cell Therapy for $\beta$ -Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier. Advances in Experimental Medicine and Biology, 2017, 1013, 219-240.	0.8	5
27	The Activated TGF $\beta$ 2 Pathway in Shwachman Diamond Syndrome Impairs Hematopoiesis and Is Down-Regulated By Deletion of 7q. Blood, 2017, 130, 875-875.	0.6	3
28	LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular Therapy - Nucleic Acids, 2016, 5, e394.	2.3	1
29	Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nature Medicine, 2016, 22, 1392-1401.	15.2	131
30	Induced pluripotent stem cells, past and future. Science, 2016, 353, 991-992.	6.0	34
31	Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy. Molecular Therapy, 2016, 24, 678-684.	3.7	175
32	Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene. Molecular Therapy - Nucleic Acids, 2016, 5, e284.	2.3	21
33	Isogenic iPSC Models of SRSF2-Mutant Myelodysplastic Syndrome Capture Disease Phenotypes, Splicing Defects and Drug Responses. Blood, 2016, 128, 962-962.	0.6	2
34	Modeling myeloid malignancies with human induced pluripotent stem cells. Experimental Hematology, 2015, 43, S39.	0.2	0
35	Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14057.	1.8	49
36	Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nature Biotechnology, 2015, 33, 646-655.	9.4	130

#	ARTICLE	IF	CITATIONS
37	The Polycomb Group Protein L3MBTL1 Represses a SMAD5-Mediated Hematopoietic Transcriptional Program in Human Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2015, 4, 658-669.	2.3	7
38	A Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies. <i>Cell Reports</i> , 2014, 8, 1677-1685.	2.9	9
39	CARs Move To the Fast Lane. <i>Molecular Therapy</i> , 2014, 22, 477-478.	3.7	4
40	An iPSC-Based Model Of MDS For Phenotype-Driven Gene and Drug Discovery. <i>Blood</i> , 2013, 122, 859-859.	0.6	0
41	Chromosome 7q Hemizygoty Recapitulates MDS-Related Cellular Phenotypes In Genetically Engineered Human Pluripotent Stem Cells. <i>Blood</i> , 2013, 122, 862-862.	0.6	0
42	FA iPSC: correction or reprogramming first?. <i>Blood</i> , 2012, 119, 5341-5342.	0.6	2
43	Transcriptional Activation by Oct4 Is Sufficient for the Maintenance and Induction of Pluripotency. <i>Cell Reports</i> , 2012, 1, 99-109.	2.9	61
44	Safe harbours for the integration of new DNA in the human genome. <i>Nature Reviews Cancer</i> , 2012, 12, 51-58.	12.8	391
45	IPS Cells From Del(7q)-MDS Patients Display Impaired Proliferation and Hematopoietic Commitment. <i>Blood</i> , 2012, 120, 174-174.	0.6	0
46	Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. <i>Nature Protocols</i> , 2011, 6, 1251-1273.	5.5	67
47	Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites. <i>Nature Protocols</i> , 2011, 6, 1274-1289.	5.5	12
48	miR-371-3 Expression Predicts Neural Differentiation Propensity in Human Pluripotent Stem Cells. <i>Cell Stem Cell</i> , 2011, 8, 695-706.	5.2	126
49	A bioinformatic assay for pluripotency in human cells. <i>Nature Methods</i> , 2011, 8, 315-317.	9.0	410
50	Genomic safe harbors permit high $\beta$ -globin transgene expression in thalassemia induced pluripotent stem cells. <i>Nature Biotechnology</i> , 2011, 29, 73-78.	9.4	277
51	A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. <i>Nucleic Acids Research</i> , 2011, 39, e72-e72.	6.5	64
52	Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients. <i>Indian Journal of Pharmacology</i> , 2011, 43, 385.	0.4	8
53	Targeting a Novel Epigenetic Silencing Mechanism to Efficiently Upregulate Fetal Globin Gene Expression. <i>Blood</i> , 2011, 118, 352-352.	0.6	0
54	A Genetic Strategy for Single and Combinatorial Analysis of miRNA Function in Mammalian Hematopoietic Stem Cells. <i>Stem Cells</i> , 2010, 28, 287-296.	1.4	77

#	ARTICLE	IF	CITATIONS
55	Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients. <i>Therapeutics and Clinical Risk Management</i> , 2010, 6, 265.	0.9	10
56	Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach. <i>International Journal of Medical Sciences</i> , 2010, 7, 94-100.	1.1	11
57	Conserved vertebrate <i>mir-451</i> provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15163-15168.	3.3	389
58	Reconstructing blood from induced pluripotent stem cells. <i>F1000 Medicine Reports</i> , 2010, 2, .	2.9	9
59	Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12759-12764.	3.3	262
60	Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. <i>Nature</i> , 2009, 461, 402-406.	13.7	808
61	Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. <i>Nature Biotechnology</i> , 2009, 27, 275-280.	9.4	3,047
62	Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. <i>Journal of Clinical Investigation</i> , 2009, 119, 157-68.	3.9	51